NextCell Pharma

Second Quarter (2024-12-01 to 2025-02-28)

• Operating income amounted to 3,417 (2,405) TSEK, of which Cellaviva contributed 3,248 (2,334) TSEK.
• Net sales amounted to 3,248 (2,334) TSEK.
• Profit/loss after financial items amounted to -8,198 (-10,093) TSEK.
• Earnings per share* were -0.11 (-0.29) SEK.
• Cash and cash equivalents amounted to 26,338 (30,393) TSEK.
• Equity ratio** amounted to 83 (79) percent.

First Half Year (2024-09-01 to 2025-02-28)

• Operating income amounted to 6,281 (7,099) TSEK, of which Cellaviva contributed 6,077 (6,580) TSEK.
• Net sales amounted to 6,077 (6,580) TSEK.
• Profit/loss after financial items amounted to -16,240 (-19,889) TSEK.
• Earnings per share* were -0.40 (-0.58) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first half year of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 28 February 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders' equity as a percentage of total assets.

Significant events and news during the second quarter

• In December, NextCell reported new results from the ProTrans-Repeat study. "The results from thePro­Trans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," com­ment- ed Mathias Svahn, CEO.
   
• Mid Februari NextCell announced that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, had been treated.

Significant events after the reporting period

• At the end of March NextCell Pharma announced today that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-in­duced pneumonia, had been treated.
   
• In the beginning of April NextCell Pharma announced preliminary one-year results from the older age group (12-21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company's cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo.
   
• NextCell Pharma announced early April that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, had been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT).
   
• Mid April NextCell Pharma published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discussed with Mathias Svahn ques­tions regarding the latest results from ProTrans-YOUNG.